EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer

By Kao Hsiang-Fong   Lin Chia-Chi   Yang James Chih-Hsin  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 991-1003

Future Medicine

Access to resources Recommend Favorite

Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer

By          

Oncology Reports, Vol. 28, Iss. 2, 2012-01 ,pp. : 721-727

Spandidos Publications

Access to resources Recommend Favorite

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG0803)

By Wu Y.-L.   Zhou C.   Cheng Y.   Lu S.   Chen G.-Y.   Huang C.   Huang Y.-S.   Yan H.-H.   Ren S.   Liu Y.   Yang J.-J.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 993-999

Oxford University Press

Access to resources Recommend Favorite

Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors

By Pilotto Sara   Bria Emilio  

Lung Cancer Management, Vol. 2, Iss. 2, 2013-04 ,pp. : 89-92

Future Medicine

Access to resources Recommend Favorite

Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292

By Furugaki Koh  

Clinical and Experimental Metastasis, Vol. 28, Iss. 7, 2011-10 ,pp. : 649-659

Springer Publishing Company

Access to resources Recommend Favorite